Position in NERV
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$879
+$877 QoQ
Shares Held
146
+14500.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2022
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NERV Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026BARCLAYS PLC holds $1,494,072,071 across 362 Biotechnology names. NERV ranks #352 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
663,263 | $296,173,457 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
313,093 | $241,908,173 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
220,623 | $72,997,531 | |
| 4 | MRNA |
Moderna, Inc.
|
932,269 | $47,359,264 | |
| 5 | INSM |
INSMED Inc
|
275,731 | $45,087,531 | |
| 6 | ROIV |
Roivant Sciences Ltd.
|
1,415,848 | $39,218,988 | |
| 7 | RVMD |
Revolution Medicines, Inc.
|
383,179 | $37,264,156 | |
| 8 | TERN |
Terns Pharmaceuticals, Inc.
|
669,601 | $35,301,364 |
All Filings in NERV
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $879 | 146 | Shares | Defined | 2026-05-15 | |
| 2025-09-30 | $2 | 1 | Shares | Sole | 2026-03-31 | |
| 2024-09-30 | $8 | 3 | Shares | Sole | 2026-03-31 | |
| 2022-06-30 | $27,903 | 8,430 | Shares | Sole | 2022-08-12 | |
| No filing history on record for this holder in this stock. | ||||||